Milatuzumab - a promising new immunotherapeutic agent, PMID: 19968579
Milatuzumab: a promising new agent for the treatment of lymphoid malignancies, PMID: 19053886
Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers, PMID: 23427296
Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines, PMID: 19351768
Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies, PMID: 23209030
Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells, PMID: 20574049
Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma, PMID: 21228331
Milatuzumab and veltuzumab induce apoptosis through JNK signalling in an NF-κB dependent human transformed follicular lymphoma cell line, PMID: 24386925
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma, PMID: 25847298
The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression, PMID: 22404985
Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas, PMID: 25754579
Prevention of acute graft-versus-host disease in a xenogeneic SCID mouse model by the humanized anti-CD74 antagonistic antibody milatuzumab, PMID: 23025988
Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma, PMID: 24112026
FTY720-induced blockage of autophagy enhances anticancer efficacy of milatuzumab in mantle cell lymphoma: is FTY720 the next autophagy-blocking agent in lymphoma treatment?, PMID: 22377620
FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death, PMID: 22042694
Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates, PMID: 26927803
A phase I-II clinical trial of the anti-CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia: A patient based approach, PMID: 28466956
Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE), PMID: 33619162
Emerging antibodies for the treatment of multiple myeloma, PMID: 27195659
Novel targeted therapies for mantle cell lymphoma, PMID: 22361516
Emerging immune targets for the treatment of multiple myeloma, PMID: 29421983
CD74: a new candidate target for the immunotherapy of B-cell neoplasms, PMID: 17875789
The secret second life of an innocent chaperone: the story of CD74 and B cell/chronic lymphocytic leukemia cell survival, PMID: 21417823
CD84 is a survival receptor for CLL cells, PMID: 23435417
Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies, PMID: 24708159
Gateways to clinical trials, PMID: 19455266
CD74 interferes with the expression of fas receptor on the surface of lymphoma cells, PMID: 25304249
ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo, PMID: 25937048
CD74 expression is increased in high-grade, invasive urothelial carcinoma of the bladder, PMID: 22905972
Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma, PMID: 19223402
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas, PMID: 22271448
The European League Against Rheumatism (EULAR) - 17th Annual European Congress of Rheumatology (June 8-11, 2016 - London, UK), PMID: 27458612
A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models., PMID:37740214
The first ADC bearing the ferroptosis inducer RSL3 as a payload with conservation of the fragile electrophilic warhead., PMID:36334452
Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE)., PMID:33619162
Emerging immune targets for the treatment of multiple myeloma., PMID:29421983
A phase I-II clinical trial of the anti-CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia: A patient based approach., PMID:28466956
The European League Against Rheumatism (EULAR) - 17th Annual European Congress of Rheumatology (June 8-11, 2016 - London, UK)., PMID:27458612
Emerging antibodies for the treatment of multiple myeloma., PMID:27195659
Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates., PMID:26927803
ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo., PMID:25937048
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma., PMID:25847298
Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas., PMID:25754579
CD74 interferes with the expression of fas receptor on the surface of lymphoma cells., PMID:25304249
Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies., PMID:24708159
Milatuzumab and veltuzumab induce apoptosis through JNK signalling in an NF-κB dependent human transformed follicular lymphoma cell line., PMID:24386925
Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma., PMID:24112026
CD84 is a survival receptor for CLL cells., PMID:23435417
Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers., PMID:23427296
Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies., PMID:23209030
Prevention of acute graft-versus-host disease in a xenogeneic SCID mouse model by the humanized anti-CD74 antagonistic antibody milatuzumab., PMID:23025988
CD74 expression is increased in high-grade, invasive urothelial carcinoma of the bladder., PMID:22905972
The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression., PMID:22404985
FTY720-induced blockage of autophagy enhances anticancer efficacy of milatuzumab in mantle cell lymphoma: is FTY720 the next autophagy-blocking agent in lymphoma treatment?, PMID:22377620
Novel targeted therapies for mantle cell lymphoma., PMID:22361516
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas., PMID:22271448
FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death., PMID:22042694
The secret second life of an innocent chaperone: the story of CD74 and B cell/chronic lymphocytic leukemia cell survival., PMID:21417823
Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma., PMID:21228331
Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells., PMID:20574049
Milatuzumab - a promising new immunotherapeutic agent., PMID:19968579
Gateways to clinical trials., PMID:19455266
Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines., PMID:19351768
Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma., PMID:19223402
Milatuzumab: a promising new agent for the treatment of lymphoid malignancies., PMID:19053886
CD74: a new candidate target for the immunotherapy of B-cell neoplasms., PMID:17875789
For research use only. Not for human or drug use.
